Bronchodilator Responsiveness Does Not Help Determine Anti-IL-5 Targeted Biologic Success in Patients With Severe Asthma

Severe asthma is usually defined as poorly controlled and refractory to treatment. It accounts for 5% to 10% of the asthma population. These patients represent a disproportional rate of morbidity, mortality, and health care resource use.1 In addition to high-dose inhaled corticosteroid-long-acting β-agonists, biologics such as anti-IgE, anti-IL-5/5R, anti-IL-4R, and anti-thymic stromal lymphopoietin are often required as step-up care for this subset of patients. The impact of biologic therapy on severe asthma has been impressive.